Nabriva Therapeutics plc (NBRV): Business Model Canvas

Key Partnerships

As a pharmaceutical company, Nabriva Therapeutics plc (NBRV) relies on strategic partnerships to drive innovation, research, and commercialization of novel antibiotics. These collaborations are essential for enhancing the company's capabilities and bringing life-saving medications to patients in need. Here are the key partnerships that fuel Nabriva's business model:

• Collaboration with pharmaceutical companies: Nabriva forms partnerships with other pharmaceutical companies to leverage their expertise, resources, and distribution channels. These collaborations often result in co-development or co-marketing agreements that help Nabriva advance its drug candidates through the clinical development process and reach a wider patient population.
• Academic and research institutions: Nabriva partners with academic and research institutions to access cutting-edge scientific research, novel drug discovery platforms, and clinical expertise. These collaborations enable Nabriva to identify new drug targets, accelerate drug development timelines, and tap into the latest advancements in antibacterial research.
• Contract research organizations: To conduct clinical trials and preclinical studies efficiently, Nabriva collaborates with contract research organizations (CROs) that specialize in drug development services. These partnerships provide Nabriva with access to specialized expertise, state-of-the-art facilities, and regulatory compliance, allowing the company to accelerate the development of its antibiotic candidates.
• Healthcare providers and hospitals: Nabriva establishes partnerships with healthcare providers, hospitals, and medical centers to gain insights into clinical practice, patient needs, and treatment patterns. These collaborations help Nabriva design clinical trials, gather real-world data, and understand the market landscape for its antibiotics. By working closely with healthcare providers, Nabriva can tailor its commercialization strategy to meet the needs of patients and healthcare professionals.

Key Activities

Nabriva Therapeutics plc focuses on several key activities to drive its business forward and achieve success in the competitive pharmaceutical industry. These activities include:

• Research and Development of Antibiotics: Nabriva is dedicated to researching and developing novel antibiotics to address the growing global threat of antibiotic resistance. This includes identifying and testing new compounds, optimizing their efficacy and safety profiles, and advancing them through preclinical and clinical development stages.
• Clinical Trials Management: Nabriva conducts clinical trials to evaluate the safety and efficacy of its antibiotics in treating various bacterial infections. This involves designing study protocols, recruiting patients, collecting and analyzing data, and reporting results to regulatory authorities.
• Regulatory Compliance: Nabriva ensures that all its activities adhere to strict regulatory requirements set forth by health authorities such as the FDA and EMA. This involves submitting applications for drug approvals, responding to regulatory inquiries, and maintaining compliance with good manufacturing practices.
• Marketing and Sales Initiatives: Nabriva develops marketing strategies to promote its antibiotics to healthcare professionals, hospitals, and patients. This includes creating educational materials, attending medical conferences, and engaging with key opinion leaders in the infectious disease field.

By effectively managing these key activities, Nabriva strives to bring innovative antibiotics to market, improve patient outcomes, and contribute to the fight against antibiotic resistance.

Key Resources

Nabriva Therapeutics plc (NBRV) relies on several key resources to drive its business model and achieve its strategic objectives. These resources include:

One of the most valuable resources for NBRV is its team of highly skilled scientists and medical professionals. These experts are responsible for developing new antibiotics and conducting clinical trials to ensure the safety and efficacy of NBRV's drug candidates.

NBRV's success is also driven by its proprietary technologies and patents. These intellectual property assets protect the company's innovations and give it a competitive edge in the market. By leveraging these technologies, NBRV can develop novel antibiotics that address unmet medical needs.

NBRV operates state-of-the-art research and development facilities where its team can conduct experiments, analyze data, and optimize drug candidates. These facilities are equipped with the latest technology and equipment, allowing NBRV to advance its pipeline of antibiotics efficiently.

To conduct clinical trials for its drug candidates, NBRV has established a network of clinical trial sites around the world. These sites allow NBRV to recruit patients, collect data, and evaluate the safety and efficacy of its antibiotics in diverse patient populations.

Overall, these key resources are essential for NBRV to continue its mission of developing innovative antibiotics to address the growing threat of antibiotic resistance.

Value Propositions

Nabriva Therapeutics plc provides innovative antibiotic treatments to address unmet medical needs in infectious diseases. The company's focus on safety and efficacy ensures that patients receive high-quality care while minimizing potential risks. Additionally, Nabriva Therapeutics plc emphasizes resistance management solutions to combat the growing issue of antibiotic resistance.

• Innovative Antibiotic Treatments: Nabriva Therapeutics plc offers groundbreaking antibiotic treatments that have the potential to transform the way infectious diseases are treated. By investing in research and development, the company stays ahead of the curve in providing cutting-edge solutions for patients.
• Unmet Medical Needs: The company's commitment to addressing unmet medical needs in infectious diseases sets it apart in the pharmaceutical industry. Nabriva Therapeutics plc focuses on developing treatments for conditions that have limited therapeutic options, ultimately improving patient outcomes.
• Safety and Efficacy: Nabriva Therapeutics plc prioritizes the safety and efficacy of its products, ensuring that patients receive the highest standard of care. By adhering to rigorous testing and regulatory standards, the company upholds its commitment to excellence in healthcare.
• Resistance Management Solutions: With the rise of antibiotic resistance posing a serious threat to public health, Nabriva Therapeutics plc is at the forefront of developing solutions to combat this issue. The company's innovative approaches to resistance management help to preserve the effectiveness of antibiotics for future generations.

Overall, Nabriva Therapeutics plc's value propositions center around providing innovative antibiotic treatments that prioritize safety, efficacy, and resistance management to address unmet medical needs in infectious diseases.

Customer Relationships

At Nabriva Therapeutics plc, we prioritize building strong relationships with healthcare professionals to ensure they trust in our products and services. We understand the importance of engaging with healthcare professionals in a meaningful and respectful way, which is why we have developed a multifaceted approach to customer relationships.

• Building trust with healthcare professionals: We strive to build trust with healthcare professionals by providing them with accurate and up-to-date information about our products. This includes conducting clinical trials, sharing data, and providing education on the benefits and risks of our products.
• Engaging through medical conferences and seminars: We actively participate in medical conferences and seminars to engage with healthcare professionals face-to-face. These events allow us to showcase our products, educate healthcare professionals on their use, and gather feedback on their experiences.
• Direct communication through sales representatives: Our dedicated sales representatives work closely with healthcare professionals to provide personalized support and information. They are trained to answer questions, address concerns, and assist with product ordering and delivery.
• Customer support and training: We offer ongoing customer support and training to healthcare professionals to ensure they are comfortable and confident in using our products. This includes online resources, in-person training sessions, and access to a dedicated support team.

Channels

Nabriva Therapeutics plc utilizes multiple channels to reach its customers and deliver its products effectively. These channels include:

• Direct sales force: Nabriva employs a dedicated team of sales representatives who engage with healthcare providers, hospitals, and pharmacies to promote and sell the company's products. This direct sales approach allows Nabriva to build relationships with key decision-makers in the healthcare industry and provide personalized support to customers.
• Online platforms for product information: Nabriva maintains a strong online presence through its website and digital marketing efforts. These platforms serve as valuable resources for healthcare professionals and patients seeking information about Nabriva's products, including their efficacy, safety, and prescribing information.
• Distributors and wholesalers: Nabriva partners with distributors and wholesalers to ensure efficient distribution of its products to healthcare facilities and pharmacies. By leveraging these partnerships, Nabriva can reach a wider network of customers and streamline the supply chain process.
• Healthcare facility partnerships: Nabriva collaborates with healthcare facilities, such as hospitals and clinics, to provide education and support regarding the use of its products. These partnerships help Nabriva establish a strong presence in the healthcare market and ensure that its products are readily available to patients in need.

Customer Segments

Nabriva Therapeutics plc targets hospitals and healthcare facilities that treat patients with bacterial infections. These institutions are essential customers as they provide a significant portion of the demand for antibiotics and other anti-infectives. By partnering with hospitals and healthcare facilities, Nabriva can ensure that its products are readily available to healthcare professionals who need them to treat their patients.

Another important customer segment for Nabriva is physicians and healthcare professionals who specialize in infectious diseases. These professionals are responsible for diagnosing and treating patients with bacterial infections, making them key decision-makers when it comes to prescribing antibiotics. Nabriva must educate and engage with this customer segment to ensure that its products are top of mind when treating bacterial infections.

Patients suffering from bacterial infections are the end users of Nabriva's products. It is crucial for Nabriva to consider the needs and preferences of these patients when developing and marketing its antibiotics. By providing effective and safe treatment options, Nabriva can build trust and loyalty with patients, leading to increased demand for its products.

Government and regulatory bodies play a significant role in the approval and distribution of antibiotics. These entities set guidelines and regulations that Nabriva must comply with to bring its products to market. Building relationships with government and regulatory bodies is essential for Nabriva to navigate the complex landscape of drug development and approval.

Cost Structure

Nabriva Therapeutics plc operates in a highly regulated industry where the development and commercialization of new antibiotics require significant investment in research and development. As a result, a substantial portion of the company's cost structure is dedicated to funding R&D activities aimed at bringing innovative antibiotic treatments to market.

1. High R&D expenditure: Nabriva allocates a significant portion of its budget towards conducting clinical trials, preclinical research, and other activities related to drug development. This includes expenses related to hiring scientific and medical experts, acquiring necessary equipment and technologies, and obtaining regulatory approvals.

2. Manufacturing and production costs: Once a drug candidate successfully completes the clinical trial process and receives regulatory approval, Nabriva incurs costs associated with manufacturing the product at scale. This includes the procurement of raw materials, facility maintenance, quality control, and distribution expenses.

3. Sales and marketing expenses: In order to successfully commercialize its antibiotic treatments, Nabriva invests in marketing and sales strategies to raise awareness among healthcare professionals and patients. This includes hiring sales representatives, conducting promotional activities, and participating in medical conferences.

4. Regulatory compliance costs: Given the stringent regulatory requirements in the pharmaceutical industry, Nabriva must allocate resources towards ensuring compliance with various laws and regulations. This includes fees for obtaining regulatory approvals, conducting audits, and maintaining quality control standards.

Overall, Nabriva's cost structure reflects the company's commitment to developing and commercializing innovative antibiotic treatments while adhering to regulatory standards and ensuring the long-term sustainability of its business operations.

Revenue Streams

Nabriva Therapeutics plc has multiple revenue streams that contribute to its overall financial success. These revenue streams include:

• Sales of approved antibiotic drugs: Nabriva generates revenue through the sales of its approved antibiotic drugs, such as Xenleta. As healthcare providers prescribe these drugs to patients, Nabriva earns revenue from the sales.
• Licensing agreements: Nabriva enters into licensing agreements with other pharmaceutical companies, allowing them to use Nabriva's technology or products for a fee. These licensing agreements provide a steady stream of revenue for the company.
• Research grants and funding: Nabriva secures research grants and funding from government agencies, non-profit organizations, and other sources to support its ongoing research and development efforts. This funding helps Nabriva to continue innovating and developing new antibiotic drugs.
• Partnership revenue: Nabriva forms partnerships with other companies in the pharmaceutical industry to collaborate on research, development, and commercialization efforts. These partnerships often involve revenue-sharing agreements, providing Nabriva with additional streams of revenue.